A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma.
Anticancer Res
; 37(7): 3397-3403, 2017 07.
Article
en En
| MEDLINE
| ID: mdl-28668827
ABSTRACT
BACKGROUND/AIM:
Anthracimycin, a secondary metabolite of Streptomyces, has been shown to inhibit the invasion of certain cancer cell lines. MATERIALS ANDMETHODS:
In this study we evaluated the effect of anthracimycin on cell growth and signaling pathways in hepatocellular carcinoma (HCC).RESULTS:
Anthracimycin suppressed cell proliferation and motility and induced apoptosis in human HCC cell lines. Furthermore, anthracimycin had no effect on the enrichment of EpCAM-high liver cancer stem cells (CSCs), while fluorouracil dramatically enriched the CSCs with activation of the stemness-related genes EPCAM and SOX9 in HuH7 cells. Mechanistically, anthracimycin suppressed mammalian target of rapamycin (mTOR) signaling, and was most effective at inhibiting HCC cell proliferation with mTOR activation.CONCLUSION:
Anthracimycin is a novel mTOR inhibitor capable of suppressing the proliferation of CSCs and non-CSCs equally well in HCC, and it is suggested that anthracimycin could be effective in the eradication of HCC associated with mTOR-signaling activation.Palabras clave
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma Hepatocelular
/
Serina-Treonina Quinasas TOR
/
Policétidos
/
Neoplasias Hepáticas
Límite:
Humans
Idioma:
En
Revista:
Anticancer Res
Año:
2017
Tipo del documento:
Article
País de afiliación:
Japón